Queen's University Investigation of Calcification in Chronic Kidney Disease (QUICK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00687661
Recruitment Status : Completed
First Posted : June 2, 2008
Last Update Posted : September 28, 2015
Information provided by (Responsible Party):
Dr. Karen Yeates, Queen's University

May 28, 2008
June 2, 2008
September 28, 2015
October 2008
June 2013   (Final data collection date for primary outcome measure)
Absolute change in coronary artery calcification score (CaSc) from baseline to study completion. [ Time Frame: 24 months ]
Same as current
Complete list of historical versions of study NCT00687661 on Archive Site
Change in bone density score (wrist/hip) as calculated by Ct scanning method, # fractures, MI, Stroke, amputation/surgery for peripheral revascularization. [ Time Frame: 24 months ]
Same as current
Not Provided
Not Provided
Queen's University Investigation of Calcification in Chronic Kidney Disease
The Use of Bisphosphonates to Prevent or Delay the Progression of Vascular Calcification in End-Stage Renal Disease: A Randomized Controlled Trial

Kidney disease is a fundamental part of medicine because of its prominence in Western society. Common conditions such as diabetes, hypertension and kidney infections can all progress to End-Stage Renal Disease (ESRD) also known as Stage 5 chronic kidney disease (CKD 5). Once ESRD has begun, kidney function is poor at best, thus the body is unable to effectively clear harmful toxins from the blood.

A common feature of ESRD is vascular calcification, a process where blood vessels (especially arteries) attract deposits of the mineral calcium. Over time, these deposits harden and thicken in the layers of blood vessels, which limit blood flow to body tissues and can produce significant disease including hypertension, heart disease and stroke. Although the process of vascular calcification is unknown, there is mounting evidence that it is mediated by cellular events that are similar to those seen in bone formation with in the body (osteogenesis). With this point in mind, it has been suggested that agents medicine employs to limit excess bone formation will reduce the rate of vascular calcification in CKD Stage 5.

This study will employ one group of drugs called bisphosphonates which have been used to limit bone formation. It will study their effect on vascular calcification in adult dialysis patients.

Presently, there exist few therapies aimed at retarding the progression of vascular calcification. One study showed that agents that limit the absorption of phosphate from food (phosphate binders) slow the progression of vascular calcification, and as a result, treatments emphasize phosphate control through diet and phosphate binders. Other studies have shown that the use of statins, to lower LDL cholesterol levels may reduce the progression of coronary calcification in non-ESRD patients, but data from ESRD are lacking. While these treatments have been helpful, the improvements in patients' outcomes have not been overwhelming positive.

This proposed study is not the first to study the use of bisphosphonates on vascular calcification. Repeated studies have shown impressive reduction in calcification rates in several animal models, which begs the question, how will bisphosphonates fare in human subjects? Preliminary research has begun, but clearly an expansive trial on humans is needed to explore the use of a promising therapy. Our study hopes to provide insight into this area of cardiovascular research.

Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Chronic Kidney Disease
  • Drug: Bisphosphonate
    35mg given orally once weekly for 24 months
    Other Name: Residronate
  • Drug: Placebo
    identical placebo pill once weekly for 24 months
  • Active Comparator: 1
    Arm #1 will include patients randomized to receive bisphosphonate therapy for 24 months.
    Intervention: Drug: Bisphosphonate
  • Placebo Comparator: 2
    Arm #2 will include patients randomized to receive placebo therapy for 24 months
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
June 2013
June 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • 18 years of age
  • receiving maintenance renal replacement therapy for less than 12 months
  • incident patients starting renal replacement therapy for the first time

Exclusion Criteria:

  • active vasculitis
  • severe hypocalcemia
  • previous adverse side effect to bisphosphonate use
  • current use of corticosteroids
  • weight greater than 300 pounds
  • pregnancy
  • not expected to survive greater than one year
  • expected to discontinue renal replacement therapy during the study period or recover renal function
  • evidence of adynamic bone disease
  • current bisphosphonate use
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
J.P.Bickell Foundation Grant
8 April 2005
Not Provided
Not Provided
Dr. Karen Yeates, Queen's University
Queen's University
Not Provided
Principal Investigator: Karen E Yeates, Dr Queen's University
Queen's University
September 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP